These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1227 related articles for article (PubMed ID: 17461704)

  • 21. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes.
    Testa L; Zoccai GB; Porto I; Trotta G; Agostoni P; Andreotti F; Crea F
    Am J Cardiol; 2007 Jun; 99(12):1637-42. PubMed ID: 17560866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?
    Nguyen MC; Lim YL; Walton A; Lefkovits J; Agnelli G; Goodman SG; Budaj A; Gulba DC; Allegrone J; Brieger D;
    Eur Heart J; 2007 Jul; 28(14):1717-22. PubMed ID: 17562671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study.
    Lorenzoni R; Lazzerini G; Cocci F; De Caterina R
    Am Heart J; 2004 Jul; 148(1):e6. PubMed ID: 15215815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
    Arch Intern Med; 1996 Feb; 156(4):409-16. PubMed ID: 8607726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
    Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Mark B; Zahn R; Senges J; Gottwik M
    Thromb Haemost; 2008 Jan; 99(1):155-60. PubMed ID: 18217148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
    Baber U; Akhter M; Kothari S; Sharma SK; Kini A
    J Invasive Cardiol; 2010 Feb; 22(2):80-3. PubMed ID: 20124594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study.
    Pérez-Gómez F; Alegría E; Berjón J; Iriarte JA; Zumalde J; Salvador A; Mataix L;
    J Am Coll Cardiol; 2004 Oct; 44(8):1557-66. PubMed ID: 15489085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis.
    Ruiz-Nodar JM; Marín F; Hurtado JA; Valencia J; Pinar E; Pineda J; Gimeno JR; Sogorb F; Valdés M; Lip GY
    J Am Coll Cardiol; 2008 Feb; 51(8):818-25. PubMed ID: 18294566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between warfarin, aspirin, and clopidogrel continuation in the peri-procedural period and the incidence of hematoma formation after device implantation.
    Thal S; Moukabary T; Boyella R; Shanmugasundaram M; Pierce MK; Thai H; Goldman S
    Pacing Clin Electrophysiol; 2010 Apr; 33(4):385-8. PubMed ID: 20059711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are glycoprotein inhibitors safe during percutaneous coronary intervention in patients on chronic warfarin treatment?
    Lahtela H; Karjalainen PP; Niemelä M; Vikman S; Kervinen K; Ylitalo A; Puurunen M; Porela P; Nyman K; Hinkka-Yli-Salomäki S; Airaksinen KE
    Thromb Haemost; 2009 Dec; 102(6):1227-33. PubMed ID: 19967155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation.
    Helft G; Gilard M; Le Feuvre C; Zaman AG
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):673-80. PubMed ID: 17122800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
    Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention?
    Steinhubl S; Berger P
    Am Heart J; 2003 Jun; 145(6):971-8. PubMed ID: 12796751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PPI use in patients commenced on clopidogrel: a retrospective cross-sectional evaluation.
    Luinstra M; Naunton M; Peterson GM; Bereznicki L
    J Clin Pharm Ther; 2010 Apr; 35(2):213-7. PubMed ID: 20456741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study).
    Tanzilli G; Greco C; Pelliccia F; Pasceri V; Barillà F; Paravati V; Pannitteri G; Gaudio C; Mangieri E
    Am J Cardiol; 2009 Nov; 104(10):1357-61. PubMed ID: 19892050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
    Rubboli A; Halperin JL
    Thromb Haemost; 2008 Nov; 100(5):752-3. PubMed ID: 18989515
    [No Abstract]   [Full Text] [Related]  

  • 39. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Best PJ; Steinhubl SR; Berger PB; Dasgupta A; Brennan DM; Szczech LA; Califf RM; Topol EJ;
    Am Heart J; 2008 Apr; 155(4):687-93. PubMed ID: 18371477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
    Roldán V; Marín F
    Thromb Haemost; 2008 Nov; 100(5):754-5. PubMed ID: 18989516
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.